EuBiologics, a vaccine development and manufacturing company, said on the 3rd that its board resolved to push ahead with building a new production facility (the third plant) to respond to the expanding global vaccine market and the commercialization of key pipelines.
Based on this third plant, it is assessed as production infrastructure for pipelines targeting advanced markets—respiratory syncytial virus (RSV), shingles, and Alzheimer's vaccines—built on revenue secured through supplies to international organizations such as UNICEF and the World Health Organization (WHO).
The company said that as supply volumes of existing global public health vaccines, such as typhoid and meningococcal, are expected to expand in earnest starting in 2028, additional production infrastructure is needed to reliably support commercial production of RSV and shingles vaccines, which aim to enter advanced markets after 2030. This production capacity is also expected to serve as a competitive edge in expanding partnerships with global pharmaceutical companies and in technology transfer negotiations.
The third plant will be built on a site secured in advance, considering the medium- to long-term scalability of the second plant. Key build-outs include: ▲ finish-dose vial production lines for typhoid and meningococcal vaccines ▲ drug substance (DS) production lines for advanced-market vaccines such as RSV, shingles, and Alzheimer's, and lyophilized vial production lines ▲ expansion of production lines for conjugate proteins and adjuvants ▲ animal cell–based biopharmaceutical drug substance contract development and manufacturing (CDMO) and antibody-drug conjugate (ADC) service lines. All facilities will be built to advanced good manufacturing practice (GMP) standards.
EuBiologics plans to invest a total of 111.5 billion won in stages over three years from 2026 to 2028. The company emphasized that this investment is a strategic facilities investment that goes beyond a simple capacity expansion to drive both medium- to long-term sales growth and profitability improvement.
A company official said, "The third plant will be a turning point for EuBiologics to leap from a public health vaccine company to a global vaccine and biopharmaceutical company focused on advanced markets," adding, "Based on stable production capacity, we will enhance medium- to long-term sales visibility and achieve structural growth that leads to increased shareholder value."